European Journal of Cancer
Volume 42, Issue 5 , Pages 582-588 , March 2006

Recent developments in the use of chemotherapy in brain tumours

  • Martin J. van den Bent

      Affiliations

    • Department of Neuro-Oncology, Daniel den Hoed Cancer Center/Erasmus University Hospital Rotterdam, P.O. Box 5201, 3008AE Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author: Tel.: +31 10 4391415; fax: +31 10 4391031.
    • ,
  • Monika E. Hegi

      Affiliations

    • Laboratory of Tumour Biology and Genetics, Department of Neurosurgery, University of Lausanne Hospitals, Lausanne, Switzerland
    • ,
  • Roger Stupp

      Affiliations

    • Multidisciplinary Oncology Center, University of Lausanne Hospitals, Lausanne, Switzerland

Received 27 June 2005 ,Accepted 29 June 2005.

References 

  1. Walker MD, Alexander E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49:333–343
  2. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303:1323–1329
  3. Glioma Meta-Analysis Group . Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011–1018
  4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996
  5. Ostermann S, Csajka C, Buclin T, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res. 2004;10:3728–3736
  6. Brada M, Judson I, Beale P, et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer. 1999;81:1022–1030
  7. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nature Rev. 2004;4:296–307
  8. Liu L, Allay E, Dumenco LL, et al. Rapid repair of O6-methylguanine–DNA adducts protects transgenic mice from N-methylnitrosourea-induced thymic lymphomas. Cancer Res. 1994;54:4648–4652
  9. Belanich M, Randall T, Pastor MA, et al. Intracellular localization and intracellular heterogeneity of the human DNA repair protein 06-methylguanine–DNA methyltransferase. Cancer Chemother Pharm. 1996;37:547–555
  10. Jaeckle KA, Eyre HJ, Townsend JJ, et al. Correlation of tumour O6 methylguanine–DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a southwest oncology group study. J Clin Oncol. 1999;16:3310–3315
  11. Belanich M, Pastor M, Randall T, et al. retrospective study of the correlation between DNA repair protein alkyltransferase and survival of brain tumour patients treated with carmustine. Cancer Res. 1996;56:783–788
  12. Silber JR, Mueller BA, Eweres TG, et al. Comparison of O6-methylguanine–DNA methyltransferase activity in brain tumours and in adjacent normal brain. Cancer Res. 1993;53:3416–3420
  13. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350–1354
  14. Hegi ME, Diserens A-C, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine–DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004;15:1871–1874
  15. Yung WKA, Prados M, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999;17:2762–2771
  16. Yung WKA, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588–593
  17. Brada M, Hoang-Xuan K, Rampling R, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol. 2000;12:259–266
  18. Brock CS, Newlands ES, Wedge SR. Phase I trial of Temozolomide using an extende continuous oral schedule. Cancer Res. 1998;58:4363–4367
  19. Vera K, Djafari L, Faivre S, et al. Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumours. Ann Oncol. 2004;15:161–171
  20. Spiro TP, Liu L, Majka S, et al. Temozolomide: the effect of once- and twice-a-day dosing on tumour tissue levels of the DNA repair protein O(6)-alkylguanine–DNA-alkyltransferase. Clin Cancer Res. 2001;7:2309–2317
  21. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine–DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88:1004–1011
  22. Khan RB, Raizer JJ, Malkin MG, et al. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-Oncology. 2002;4:39–43
  23. Wick W, Steinbach JP, Küker WM, et al. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology. 2004;62:2113–2115
  24. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol. 2004;15:610–616
  25. Mahindra AK, Grossman SA. Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumours. J Neuro-Oncol. 2003;63:263–270
  26. Stupp R, Dietrich P-Y, Osterman-Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20:1375–1382
  27. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003
  28. Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch repair and 06-alkylguanine–DNA alkyltransferase and response to temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998;16:3851–3857
  29. Chinot O-L, Barrie M, Frauger E, et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in elderly populations. Cancer. 2004;100:2208–2214
  30. Glantz M, Chamberlain M, Liu Q, et al. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer. 2003;97:2262–2266
  31. Roa W, Brasher PMA, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22:1583–1588
  32. Chang EL, Yi W, Allen PK, et al. Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: outcome and prognostic factors. Int J Radiat Oncol Biol Phys. 2003;56:519–528
  33. Brandes AA, Basso U, Reni M, et al. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol. 2004;22:1598–1604
  34. Groves MD, Puduvalli VK, Hess KR, et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol. 2002;20:1383–1388
  35. Jaeckle KA, Hess KR, Yung WKA, et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumour Consortium Study. J Clin Oncol. 2003;21:2305–2311
  36. Fine HA, Wen PY, Maher EA, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol. 2003;21:2299–2304
  37. Quinn JA, Pluda J, Dolan ME, et al. Phase II trial of carmustine plus O6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol. 2002;20:2277–2283
  38. Clifford Schold S, Kuhn JG, Chang SM, et al. A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North-American brain tumour consortium study. Neuro-Oncology. 2000;2:34
  39. Friedman HS, Pluda J, Quinn JA, et al. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2000;18:3522–3528
  40. Quinn JA, Desjardins A, Reardon D, et al. Phase II trial of temozolomide (temodar) plus O6-benzylguanine in the treatment of patients with temodar-resistant malignant glioma. Neuro-Oncology. 2004;6:380;(Abstract TA-45)
  41. Prados MD, Yung WKA, Fine HA, et al. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumour Consortium study. Neuro-Oncology. 2004;6:33–37
  42. Friedman HS, Petros WP, Friedman A, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999;17:1516–1525
  43. Raymond E, Fabbro M, Boige V, et al. Multicentre phase II study abd pharmacokinetic analysis of irinotecan in chemotherapy-naı¨ve patients with glioblastoma. Ann Oncol. 2003;14:603–614
  44. Chamberlain M. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neuro-Oncol. 2002;56:183–188
  45. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol. 1994;12:2013–2021
  46. van den Bent MJ, Kros JM, Heimans JJ, et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU and vincristine chemotherapy. Neurology. 1998;51:1140–1145
  47. Möllemann M, Wolter M, Felsberg J, et al. Frequent promotor hypermethylation and low expression of the MGMT gene in oligodendroglial tumours. Int J Cancer. 2004;113:379–385
  48. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473–1479
  49. van den Bent MJ, Looijenga LHJ, Langenberg K, et al. Chromosomal anomalies in oligodendroglial tumours are correlated with clinical features. Cancer. 2003;97:1276–1284
  50. van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglioma: the European Organisation of Research and Treatment of Cancer Brain Tumour Group study 26971. J Clin Oncol. 2003;21:2525–2528
  51. van den Bent MJ, Chinot O, Boogerd W, et al. Second-line chemotherapy with Temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumour Group phase II study 26972. Ann Oncol. 2003;14:599–602
  52. Triebels V, Taphoorn MJB, Brandes AA, et al. Response to 2nd line PCV chemotherapy in recurrent oligodendroglioma after 1st line temozolomide. Neurology. 2004;63:904–906
  53. Cairncross JG, Seiferheld W, Shaw E, et al. An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: initial report of RTOG 94-02. Proc Am Soc Clin Oncol. 2004;23:107;(Abstract # 1500)
  54. Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet. 2002;360:1361–1368
  55. Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol. 2003;14:1715–1721
  56. Biemond-ter Stege E, Kros JM, de Bruin HG, et al. Treatment of low-grade oligodendroglial tumours with PCV chemotherapy. Cancer. 2005;103:802–809
  57. Buckner JC, Gesme D, O’Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and and associations with chromosomal abnormalities. J Clin Oncol. 2003;21:251–255
  58. Hoang-Xuan K, Capelle L, kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004;22:3133–3138
  59. Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol. 2003;14:1722–1726
  60. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol. 2003;21:646–651
  61. Brandes AA, Tosoni A, Amista P, et al. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology. 2004;63:1281–1284
  62. Brandes AA, Tosoni A, Basso U, et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol. 2004;22:4779–4786
  63. Kappele AC, Postma TJ, Taphoorn MJ, et al. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology. 2001;56:118–120

PII: S0959-8049(05)01080-4

doi: 10.1016/j.ejca.2005.06.031

European Journal of Cancer
Volume 42, Issue 5 , Pages 582-588 , March 2006

Article Tools